Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
The review deals with trials of pegylated liposomal doxorubicin (PLD) used to treat metastatic breast cancer (mBC), including first-line monotherapy, maintenance therapy, combinations with other cytostatics, trastuzumab regimens for a HER-2-positive subvariant, and rescue therapy for intensively pre...
Saved in:
Main Author: | E. V. Artamonova (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2016-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pegylated liposomal doxorubicin in ovarian cancer
by: Robert Strother, et al.
Published: (2009) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
by: Gabriella Ferrandina, et al.
Published: (2010) -
Pharmacoeconomics analysis of pegylated liposomal doxorubicin (Caelyx®) in the treatment of patients with metastatic breast cancer at high risk of cardiac events
by: I. S. Krysanov
Published: (2018) -
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021) -
Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
by: S. Yost, et al.
Published: (2019)